Publication:
Trunk melanomas: no survival differences between lesion sites

dc.contributor.coauthorTaş, Faruk
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorErtürk, Kayhan
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:25:31Z
dc.date.issued2022
dc.description.abstractObjectives The anatomic site of primary melanoma is significantly associated with patient survival, e.g. trunk melanomas have poorer prognosis than limb melanomas. The aim of this study was to evaluate the clinicopathological factors and survival outcomes of trunk melanoma patients and to identify the differences between anatomical areas of the trunk. Methods A total of 491 trunk melanomas were analyzed retrospectively. Results The median age was 49 years. The 5-year relapse-free survival rate was 58.3% for all patients, which was 60%, 53.1%, 56.5%, 60.1%, and 66.1% for chest, abdominal, dorsal, lumbar, and gluteal melanoma patients, respectively (p = 0.8). The 5-year overall survival rate was 61.1% for all patients, which was 62.6%, 57.4%, 59.1%, 66.9%, and 72.1% for chest, abdominal, dorsal, lumbar, and gluteal melanoma patients, respectively (p = 0.3). The unfavorable pathological and clinical prognostic factors, such as sex (p = 0.0001), histology (p = 0.0001), Clark level (p = 0.0001), Breslow depth (p = 0.0001), mitotic rate (p = 0.002), ulceration (0.0001), lymphovascular invasion (p = 0.01), BRAF mutation (p = 0.01), lymph node positivity (p = 0.0001), metastasis (p = 0.0001), and relapse (p = 0.0001), were found to be associated with overall survival. Conclusion Trunk melanomas may be associated with aggressive pathological and poor clinical features, such as thickness, mitotic rate, ulceration, and advanced clinical stages; therefore, they predict unfavorable survival rates regardless of anatomical sites.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue6
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume134
dc.identifier.doi10.1080/00325481.2022.2080380
dc.identifier.eissn1941-9260
dc.identifier.issn0032-5481
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85131445408
dc.identifier.urihttps://doi.org/10.1080/00325481.2022.2080380
dc.identifier.urihttps://hdl.handle.net/20.500.14288/11373
dc.identifier.wos805272300001
dc.keywordsMelanoma
dc.keywordsTrunk
dc.keywordsPrognostic factor
dc.keywordsSurvival
dc.language.isoeng
dc.publisherTaylor & Francis
dc.relation.ispartofPostgraduate Medicine
dc.subjectMedicine
dc.subjectGeneral
dc.subjectInternal
dc.titleTrunk melanomas: no survival differences between lesion sites
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorErtürk, Kayhan
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files